Dhodapkar MV - Search Results

1

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Dhodapkar MV, et al. Blood. 2001 Jul 1;98(1):41-8. doi: 10.1182/blood.v98.1.41. Blood. 2001. PMID: 11418461 Free article. Clinical Trial.

2

Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion.

Dhodapkar M, Goldberg SL, Tefferi A, Gertz MA. Dhodapkar M, et al. Am J Hematol. 1994 Feb;45(2):187-8. doi: 10.1002/ajh.2830450218. Am J Hematol. 1994. PMID: 7908165

3

Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.

Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Dhodapkar MV, et al. Br J Haematol. 1997 Nov;99(2):368-71. doi: 10.1046/j.1365-2141.1997.3893203.x. Br J Haematol. 1997. PMID: 9375756 Free article.

4

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, Barlogie B, Tricot G. Desikan KR, et al. Among authors: dhodapkar mv. Leuk Lymphoma. 1997 Oct;27(3-4):315-9. doi: 10.3109/10428199709059685. Leuk Lymphoma. 1997. PMID: 9402328 Clinical Trial.

5

Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.

Dhodapkar MV, Jagannath S, Vesole D, Munshi N, Naucke S, Tricot G, Barlogie B. Dhodapkar MV, et al. Leuk Lymphoma. 1997 Oct;27(3-4):351-6. doi: 10.3109/10428199709059690. Leuk Lymphoma. 1997. PMID: 9402333 Clinical Trial.

6

The systemic amyloidoses.

Dhodapkar M, Barlogie B, Gertz M. Dhodapkar M, et al. N Engl J Med. 1998 Jan 22;338(4):264; author reply 264-5. doi: 10.1056/NEJM199801223380414. N Engl J Med. 1998. PMID: 9441241 No abstract available.

7

Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.

Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD. Dhodapkar MV, et al. Blood. 1998 Apr 15;91(8):2679-88. Blood. 1998. PMID: 9531576 Free article.

8

Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.

Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D. Rudnicki SA, et al. Neurology. 1998 Oct;51(4):1210-3. doi: 10.1212/wnl.51.4.1210. Neurology. 1998. PMID: 9781565

9

Recent advances in the treatment of multiple myeloma.

Desikan KR, Dhodapkar MV, Munshi NC, Barlogie B. Desikan KR, et al. Among authors: dhodapkar mv. Curr Opin Hematol. 1999 Jul;6(4):216-21. doi: 10.1097/00062752-199907000-00004. Curr Opin Hematol. 1999. PMID: 10400369 Review.

10

High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia.

Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B, Munshi NC. Desikan R, et al. Br J Haematol. 1999 Jun;105(4):993-6. doi: 10.1046/j.1365-2141.1999.01461.x. Br J Haematol. 1999. PMID: 10554812 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters